Literature DB >> 2865092

Pharmacology of the treatment of peptic ulcer disease.

G Bertaccini, G Coruzzi.   

Abstract

Anti-ulcer drugs may be classified according to their site and/or mechanism of action as: corticohypothalamic drugs; antisecretory drugs which may be anticholinergic agents (both classical atropine-like compounds and pirenzepine) or antagonists of the H2-receptors; antacids; agents which protect the mucosa; and gastric muscle stimulants. New groups of compounds with different pharmacokinetics and mechanisms of action are currently being investigated, and it is possible that they will represent an alternative to, or a substitute for, the present widely used anti-ulcer drugs. Among the new drugs, synthetic prostaglandins are probably the most interesting compounds, having potent antisecretory activity together with important cytoprotective properties. Another interesting group are the inhibitors of H+/K+-ATPase such as the substituted benzimidazoles, among which omeprazole is characterized by potent and long-acting antisecretory activity. Theoretically, other drugs such as calcium-entry blockers and synthetic somatostatin analogs deserve consideration although results obtained are preliminary.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2865092     DOI: 10.1007/bf01309384

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  20 in total

1.  Cytoprotection by prostaglandins.

Authors:  A Robert
Journal:  Gastroenterology       Date:  1979-10       Impact factor: 22.682

2.  Definition and antagonism of histamine H 2 -receptors.

Authors:  J W Black; W A Duncan; C J Durant; C R Ganellin; E M Parsons
Journal:  Nature       Date:  1972-04-21       Impact factor: 49.962

3.  A bismuth-peptide complex in the treatment of duodenal ulceration. A double-blind duodenoscopic study.

Authors:  M G Moshal
Journal:  S Afr Med J       Date:  1975-07-12

4.  Muscarinic receptor subtypes: M1 and M2 biochemical and functional characterization.

Authors:  R Hammer; A Giachetti
Journal:  Life Sci       Date:  1982-12-27       Impact factor: 5.037

5.  Effect of verapamil on gastric secretion in man.

Authors:  E Aadland; A Berstad
Journal:  Scand J Gastroenterol       Date:  1983-10       Impact factor: 2.423

6.  Increased healing of gastric and duodenal ulcers in a controlled trial using tripotassium dicitrato-bismuthate.

Authors:  S P Lee; G I Nicholson
Journal:  Med J Aust       Date:  1977-05-28       Impact factor: 7.738

7.  Calcium and stimulus-secretion coupling in gastric fundic mucosa. Effect of inhibition of calcium transport by verapamil on gastric acid secretion in the isolated guinea pig fundic mucosa and in healthy subjects.

Authors:  P Kirkegaard; J Christiansen; B Petersen; P Skov Olsen
Journal:  Scand J Gastroenterol       Date:  1982-06       Impact factor: 2.423

8.  The inhibitory effects of 5-hydroxytryptamine on gastric acid secretion by the rat isolated stomach.

Authors:  S P Canfield; J E Spencer
Journal:  Br J Pharmacol       Date:  1983-01       Impact factor: 8.739

9.  Effect of verapamil on basal and pentagastrin-stimulated gastric acid secretion.

Authors:  R A Levine; S Petokas; A Starr; R H Eich
Journal:  Clin Pharmacol Ther       Date:  1983-09       Impact factor: 6.875

10.  Comparison of the healing capacities of sucralfate and cimetidine in the short-term treatment of duodenal ulcer: a double-blind randomized trial.

Authors:  F Martin; A Farley; M Gagnon; D Bensemana
Journal:  Gastroenterology       Date:  1982-03       Impact factor: 22.682

View more
  5 in total

1.  Probenecid Reduces Alcohol Drinking in Rodents. Is Pannexin1 a Novel Therapeutic Target for Alcohol Use Disorder?

Authors:  Brendan J Tunstall; Irene Lorrai; Sam A McConnell; Katrina L Gazo; Lia J Zallar; Giordano de Guglielmo; Ivy Hoang; Carolina L Haass-Koffler; Vez Repunte-Canonigo; George F Koob; Leandro F Vendruscolo; Pietro Paolo Sanna
Journal:  Alcohol Alcohol       Date:  2019-01-09       Impact factor: 2.826

2.  Evaluation of antisecretory activity of misoprostol in duodenal ulcer patients using long-term intragastric pH monitoring.

Authors:  V Savarino; P Scalabrini; G S Mela; E di Timoteo; G Percario; M R Magnolia; G Celle
Journal:  Dig Dis Sci       Date:  1988-03       Impact factor: 3.199

3.  A drug library screen identifies Carbenoxolone as novel FOXO inhibitor that overcomes FOXO3-mediated chemoprotection in high-stage neuroblastoma.

Authors:  Stefan Salcher; Gilles Spoden; Judith Hagenbuchner; Sebastian Führer; Teresa Kaserer; Martin Tollinger; Petra Huber-Cantonati; Thomas Gruber; Daniela Schuster; Ronald Gust; Heinz Zwierzina; Thomas Müller; Ursula Kiechl-Kohlendorfer; Michael J Ausserlechner; Petra Obexer
Journal:  Oncogene       Date:  2019-10-07       Impact factor: 9.867

4.  11β-hydroxysteroid dehydrogenase inhibition as a new potential therapeutic target for alcohol abuse.

Authors:  P P Sanna; T Kawamura; J Chen; G F Koob; A J Roberts; L F Vendruscolo; V Repunte-Canonigo
Journal:  Transl Psychiatry       Date:  2016-03-15       Impact factor: 6.222

5.  Sulforaphane Inhibits HIV Infection of Macrophages through Nrf2.

Authors:  Andrea Kinga Marias Furuya; Hamayun J Sharifi; Robert M Jellinger; Paul Cristofano; Binshan Shi; Carlos M C de Noronha
Journal:  PLoS Pathog       Date:  2016-04-19       Impact factor: 6.823

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.